Last year, we had at ASCO, which is the Florida Society of Association of Clinical Oncology, we collaborated with around 18 different centers in the state of Florida, again with support from Pfizer, and we wanted to look into how HRR testing uptake is in different centers across the state for stage four metastatic prostate cancer. Guidelines currently say that all patients who are diagnosed, whether it’s de novo or who are transformed into stage four metastatic disease, should have HRR testing, but the data showed in 2022 it was around only 30 %, which is very low...
Last year, we had at ASCO, which is the Florida Society of Association of Clinical Oncology, we collaborated with around 18 different centers in the state of Florida, again with support from Pfizer, and we wanted to look into how HRR testing uptake is in different centers across the state for stage four metastatic prostate cancer. Guidelines currently say that all patients who are diagnosed, whether it’s de novo or who are transformed into stage four metastatic disease, should have HRR testing, but the data showed in 2022 it was around only 30 %, which is very low. So we collaborated and we were trying to identify through a survey what the different barriers are, why it’s not happening. We were able to see that a lot of those barriers are in logistics, whether in documentation of EMR orders in EMR, and so on. So we internally collaborated as well and we looked into what different initiatives are happening at Sylvester Cancer Center. In the past two years, Sylvester has been trying to increase the Epic genomic module. We have a data repository where all genomic testing is deposited in one place, which can help us in research, clinical work, clinical trials, and so on. We have now an electronic method of ordering all those different tests as well, and soon we will be integrating all those tests purely into Epic as well. So with all those different initiatives, we saw just in the past two years that the percentage even in our own center went from 50% to 80%. So this was a big system-wide implementation project, and we are still going to keep on working on it to get to the 100% mark.
